European Union: Infringement Of Second Medical Use Claims In Europe

It is possible to obtain a patent from the European Patent Office (EPO) based on a new medical use of a known drug. The claim can be directed to using the drug to treat a different disease, or using the drug in a new method of treatment, such as a new route of administration or a new dosage. The EPO has well-established requirements for the patentability of these so-called "second medical use" claims, but it does not consider issues of patent infringement. Infringement in Europe is currently assessed on a country-by-country basis by individual national courts.

Although these second medical use claims have been available in Europe since the 1980s, until recently it has been unclear how the manufacture and sale of a drug for a patented use can be distinguished in practice from the manufacture and sale of the same drug for a non-patented use. The English Court of Appeal has now clarified how infringement of such second medical use claims should be assessed in the United Kingdom.1

The Pregabalin Case in the United Kingdom

As discussed in our earlier article,2 Warner-Lambert has been involved in litigation across Europe relating to a second medical use patent granted by the EPO, directed to the use of pregabalin in the manufacture of a medicament for treating pain.

Pregabalin is approved for use in the United Kingdom in the treatment of general anxiety disorder (GAD), epilepsy, and neuropathic pain. Actavis was sued for infringement by Warner-Lambert after it applied for approval to sell pregabalin in the UK under a "skinny label" that referred only to the treatment of GAD and epilepsy, not covered by Warner-Lambert's patent. Warner-Lambert argued that the Actavis product would inevitably be used by physicians and prescribed by pharmacists for the treatment of pain, even though that treatment was not specifically mentioned on the product packaging.

The Court of Appeal concluded that Warner-Lambert's patent was invalid, and so there was no requirement to consider infringement. However, it took the opportunity to clarify the test that should be applied when considering infringement in this situation. The Court acknowledged that it is not straightforward to find a suitable balance between the needs of the parties: "The law is struggling on the one hand to give the patentee a proper reward for his contribution to the art by elucidating the new use for the drug, whilst at the same time not excluding the competing manufacturer from making and marketing the drug for its known purpose."

A key issue was whether a second medical use claim will only be infringed when it can be shown that the manufacturer specifically intends for its product to be used to treat the patented indication. The Court reviewed decisions from a number of other European courts that considered this issue, but found a variety of different approaches. In some cases, only the uses stated on the product packaging were taken into account, others looked at whether there was some element of encouragement by the manufacturer, and others considered whether steps had been taken by the manufacturer to prevent use for the patented indication.

The Court concluded that the question to be considered was whether Actavis knew, or could foresee, that at least some of the prescriptions written generically for pregabalin to treat pain would be fulfilled with its drug. The Court recognised an obligation on a manufacturer to take active steps if it is to enter a market where it stands to benefit from the patentee's patented invention. In order to avoid infringement, the manufacturer must show that it has taken all reasonable steps in its power to prevent its drug from being used in accordance with the patent.

What Must Be Done To Avoid Infringing Uses?

The approach proposed by the UK Court is consistent with the findings in related French proceedings,3 which assessed what another manufacturer, Sandoz, had done to prevent use of its pregabalin product for the patented indication in France. Sandoz had sent an information email to doctors and pharmacists prior to launch, stating that its product was not indicated for neuropathic pain. Sandoz had also agreed to send more explicit messages to physicians and pharmacists to describe how to prescribe or dispense its drug, in order to avoid infringement. Although Sandoz had a larger share of the market than was represented by non-pain use, the French court concluded that Sandoz had done enough to avoid direct infringement of Warner-Lambert's patent.

It is not clear from the UK decision what steps a manufacturer might need to take in the UK to establish that it did not intend for its product to be used for a patented indication. There is clearly a burden on the manufacturer to try to limit the use of its product to the non-patented uses. However, the Court's test does suggest that factors that are outside the control of the manufacturer, such as those based on the structure and processes of the healthcare system, will not be held against it.

In view of the flexibility that is afforded to individual doctors and pharmacists in the UK, it is unlikely that the efforts required by this test will be able to completely prevent the off-label use of generic products for patented uses. In some cases, patentees may need to consider taking further action themselves to enforce the prescription of only their approved drug for the patented use. For example, Pfizer has successfully obtained an injunction in the UK against NHS England (which oversees the operations of the English National Health Service), requiring them to instruct doctors to prescribe pregabalin only by the Pfizer brand name Lyrica when it is for use in treating pain.4

Despite the inability to completely prevent physicians and pharmacists from prescribing a generic drug for a patented indication, it is clear from this decision that a second medical use patent can be valuable. It can impose a burden on other manufacturers to try to prevent their products being used in accordance with the patent. A patent filing strategy involving follow-up patent applications directed to specific uses of a drug can therefore limit, or at least disrupt, the market for third party products, even after the basic patent protection for the product itself has expired.

Footnotes

1. Warner-Lambert Company LLC v Generics (UK) Ltd

. (t/a Mylan) & Ors [2016] EWCA Civ 1006 (13 October 2016)

2. Infringement of Second Medical Use Claims in the United Kingdom - Full Disclosure Patent Newsletter, November 2015

3. Warner-Lambert Company & Pfizer v. Sandoz, order of the presiding judge of the Tribunal de Grande Instance de Paris of 26 October 2015, Docket № 15/58725

4Warner-Lambert Co. v. Actavis Grp. Ptc EHF [2015] EWHC 485 (Pat).

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Events from this Firm
2 Nov 2017, Webinar, Washington, DC, United States

Join us for a two-part webinar series exploring recent developments in machine learning and other technologies that have greatly advanced artificial intelligence (AI) since its origins more than 50 years ago.

9 Nov 2017, Webinar, Washington, DC, United States

As part of Strafford Publications’ webinar series, Finnegan attorneys Adriana Burgy, Chris Johns, and Kai Rajan will discuss the Examiner Count System and provide strategies for interacting with examiners.

15 Nov 2017, Conference, California, United States

Finnegan is a Gold sponsor of the second annual Digital Media & IP Forum, hosted by World Congress.

 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.